DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mucomyst (Acetylcysteine Inhalation) - Published Studies

 
 



Mucomyst Related Published Studies

Well-designed clinical trials related to Mucomyst (Acetylcysteine Inhalation)

Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. [2015]

Long-term treatment with oral N-acetylcysteine: Affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. [2014]

Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. [2014]

Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. [2014]

Effects of N-acetylcysteine on the cardiac remodeling biomarkers and major adverse events following acute myocardial infarction: a randomized clinical trial. [2014]

N-Acetylcysteine and metabotropic glutamate receptors: implications for the treatment of schizophrenia: a literature review. [2014]

A double-blind placebo-controlled trial of N-acetylcysteine in the treatment of cocaine dependence. [2013]

N-acetylcysteine plus intravenous fluids versus intravenous fluids alone to prevent contrast-induced nephropathy in emergency computed tomography. [2013]

Prophylactic high-dose oral-N-acetylcysteine does not prevent atrial fibrillation after heart surgery: a prospective double blind placebo-controlled randomized clinical trial. [2013]

N-acetylcysteine versus placebo for treating nail biting, a double blind randomized placebo controlled clinical trial. [2013]

High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. [2013]

Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. [2013]

Use of acetylcysteine for non-acetaminophen-induced acute liver failure. [2013]

High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study. [2013]

Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. [2013]

The Effects of N-Acetylcysteine and Deferoxamine on Plasma Cytokine and Oxidative Damage Parameters in Critically Ill Patients With Prolonged Hypotension: A Randomized Controlled Trial. [2011.11.01]

Effect of N-acetylcysteine on cardiac injury and oxidative stress after abdominal aortic aneurysm repair: A randomized controlled trial. [2011.09]

Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. [2011.07]

A randomized trial of intravenous N-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes. [2011.05.03]

Effect of N-acetylcysteine treatment on the expression of leukocyte surface markers after burn injury. [2011.05]

N-acetylcysteine in handgrip exercise: plasma thiols and adverse reactions. [2011.04]

Effect of N-acetylcysteine on pulmonary function in patients undergoing off-pump coronary artery bypass surgery. [2011.04]

Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study. [2011.04]

The role of preconditioning and N-acetylcysteine on oxidative stress resulting from tourniquet-induced ischemia-reperfusion in arthroscopic knee surgery. [2011.03]

Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction? [2011]

Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. [2011]

Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: a randomized multicenter controlled trial. [2010.12]

Potential benefits of combined N-acetylcysteine and ciprofloxacin therapy in partial biliary obstruction. [2010.12]

Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS-A multicenter prospective controlled trial. [2010.11.22]

Relative bioavailability of generic and branded acetylcysteine effervescent tablets: A single-dose, open-label, randomized-sequence, two-period crossover study in fasting healthy Chinese male volunteers. [2010.11]

N-acetylcysteine does not prevent renal dysfunction after off-pump coronary artery bypass surgery. [2010.11]

Effect of N-acetylcysteine on serum creatinine and kidney function: results of a randomized controlled trial. [2010.10]

N-acetylcysteine fails to prevent renal dysfunction and oxidative stress after noniodine contrast media administration during percutaneous coronary interventions. [2010.10]

Intraoperative pH values after N-acetylcysteine administration during liver transplantation. [2010.10]

Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity. [2010.10]

Qualitative methods in early-phase drug trials: broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia. [2010.09.21]

Oxidative stress in hemodialysis patients receiving intravenous iron therapy and the role of N-acetylcysteine in preventing oxidative stress. [2010.09]

Multiple-dose pharmacokinetics and pharmacodynamics of N-acetylcysteine in patients with end-stage renal disease. [2010.09]

Enteral nutrition with or without N-acetylcysteine in the treatment of severe acute alcoholic hepatitis: A randomized multicenter controlled trial. [2010.08.01]

Efficacy of topical N-acetylcysteine in the treatment of meibomian gland dysfunction. [2010.08]

The efficacy of n-acetylcysteine in preventing contrast-induced nephropathy in type 2 diabetic patients without nephropathy. [2010.07]

N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. [2010.07]

Preventing cisplatin induced ototoxicity by N-acetylcysteine and salicylate. [2010.07]

The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. [2010.07]

Effects of N-acetylcysteine on asthma exacerbation. [2010.06]

Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate PercutaneouS Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. [2010.05.18]

N-Acetylcysteine infusion does not affect glucose disposal during prolonged moderate-intensity exercise in humans. [2010.05.01]

N-acetylcysteine and magnesium improve biochemical abnormalities associated with myocardial ischaemic reperfusion in South Indian patients undergoing coronary artery bypass grafting: a comparative analysis. [2010.05]

Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study. [2010.05]

Effects of N-acetylcysteine on renal dysfunction in neonates undergoing the arterial switch operation. [2010.04]

Efficacy of N-acetylcysteine and aminophylline in preventing contrast-induced nephropathy. [2010.03]

Modulatory effect of N-acetylcysteine on pro-antioxidant status and haematological response in healthy men. [2010.03]

N-acetylcysteine: short-term clinical benefits after coronary angiography in high-risk renal patients. [2010.01]

The effect of N-acetylcysteine on blood pressure and markers of cardiovascular risk in non-diabetic patients with chronic kidney disease: a placebo-controlled, randomized, cross-over study. [2010]

Ischemia-modified albumin reduction after coronary bypass surgery is associated with the cardioprotective efficacy of cold-blood cardioplegia enriched with N-acetylcysteine: a preliminary study. [2010]

N-acetylcysteine does not prevent hepatorenal ischaemia-reperfusion injury in patients undergoing orthotopic liver transplantation. [2010]

N-Acetylcysteine as adjunctive treatment in severe malaria: A randomized, double-blinded placebo-controlled clinical trial. [2009.12.26]

Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. [2009.11]

Acetylcysteine and non-ionic isosmolar contrast-induced nephropathy--a randomized controlled study. [2009.10]

Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. [2009.09]

N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. [2009.09]

Effect of N-acetylcysteine in attenuating ischemic reperfusion injury in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. [2009.09]

A phase II study on safety and efficacy of high-dose N-acetylcysteine in patients with cystic fibrosis. [2009.08.12]

Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. [2009.08]

N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. [2009.07]

Potentially detrimental effects of N-acetylcysteine on renal function in knee arthroplasty. [2009.07]

Effects of N-acetylcysteine on semen parameters and oxidative/antioxidant status. [2009.07]

N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. [2009.06.29]

N-acetylcysteine is associated with increased blood loss and blood product utilization during cardiac surgery. [2009.06]

Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis. [2009.04]

N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. [2009.03]

The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. [2009.03]

N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. [2009.02]

Effects of N-acetylcysteine on respiratory muscle fatigue during heavy exercise. [2009.01.01]

Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery. [2009.01]

Blood cardioplegia with N-acetylcysteine may reduce coronary endothelial activation and myocardial oxidative stress. [2009.01]

Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. [2009.01]

N-acetylcysteine improves arterial vascular reactivity in patients with chronic kidney disease. [2009]

The comparison of antioxidant and hematological properties of N-acetylcysteine and alpha-lipoic acid in physically active males. [2009]

Poorly controlled type 1 diabetes is associated with altered glutathione homeostasis in adolescents: apparent resistance to N-acetylcysteine supplementation. [2008.12]

The effects of low dose N-acetylcysteine (NAC) as an adjunct to cardioplegia in coronary artery bypass surgery. [2008.12]

Is treatment with N-acetylcysteine to prevent contrast-induced nephropathy when using bicarbonate hydration out of date? [2008.12]

N-acetylcysteine improves the clinical conditions of mustard gas-exposed patients with normal pulmonary function test. [2008.11]

Effect of N-acetylcysteine administration on intraoperative plasma levels of interleukin-4 and interleukin-10 in liver transplant recipients. [2008.11]

N-acetylcysteine supplementation and oxidative damage and inflammatory response after eccentric exercise. [2008.08]

Effects of intravenous N-acetylcysteine on periprocedural myocardial injury after on-pump coronary artery by-pass grafting. [2008.08]

Meta-analysis of N-Acetylcysteine to Prevent Acute Renal Failure After Major Surgery. [2008.07.21]

Inhaled thiamphenicol and acetylcysteine in children with acute bacterial rhinopharyngitis. [2008.07]

Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: a prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine. [2008.06.06]

Randomized, blinded, placebo-controlled clinical trial of N-acetylcysteine in dogs with spinal cord trauma from acute intervertebral disc disease. [2008.06.01]

Randomized, blinded, placebo-controlled clinical trial of N-acetylcysteine in dogs with spinal cord trauma from acute intervertebral disc disease. [2008.06.01]

Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. [2008.06]

N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery. [2008.05]

N-Acetylcysteine does not artifactually lower plasma creatinine concentration. [2008.05]

Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. [2008.05]

Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results. [2008.04]

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients. [2008.01]

N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. [2008.01]

The effect of N-acetylcysteine on proteinuria and markers of tubular injury in non-diabetic patients with chronic kidney disease. A placebo-controlled, randomized, open, cross-over study. [2008]

Effects of folic acid and N-acetylcysteine on plasma homocysteine levels and endothelial function in patients with coronary artery disease. [2007.12]

N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. [2007.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017